Technical Analysis for TRIL - Trillium Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
7.26 | 0.41% | 0.03 |
TRIL closed up 0.41 percent on Friday, July 10, 2020, on 47 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Historical TRIL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Support | Bullish | 0.41% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.41% | |
| Bollinger Band Squeeze | Range Contraction | 0.41% | |
| Oversold Stochastic | Weakness | 0.41% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2019
- Sector: Healthcare
- Industry: Biotechnology
Trillium Therapeutics Inc. is an immuno-oncology company developing innovative
therapies for the treatment of cancer. The Company has two premier preclinical
programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the host immune system.
SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule
that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other
malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the
activity of CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors.
For more information visit: www.trilliumtherapeutics.com
Medicine Cancer Medical Specialties Immunology Treatment Of Cancer Immune System Tumor Acute Myeloid Leukemia Cancer Immunotherapy Monoclonal Antibody Antibody Drug Conjugates Cancer Research CD47
Medicine Cancer Medical Specialties Immunology Treatment Of Cancer Immune System Tumor Acute Myeloid Leukemia Cancer Immunotherapy Monoclonal Antibody Antibody Drug Conjugates Cancer Research CD47
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.66 |
| 52 Week Low | 0.24 |
| Average Volume | 2,062,623 |
| 200-Day Moving Average | 3.51 |
| 50-Day Moving Average | 7.11 |
| 20-Day Moving Average | 8.00 |
| 10-Day Moving Average | 7.61 |
| Average True Range | 0.67 |
| ADX | 19.97 |
| +DI | 19.37 |
| -DI | 19.11 |
| Chandelier Exit (Long, 3 ATRs ) | 7.66 |
| Chandelier Exit (Short, 3 ATRs ) | 9.05 |
| Upper Bollinger Band | 9.14 |
| Lower Bollinger Band | 6.86 |
| Percent B (%b) | 0.17 |
| BandWidth | 28.49 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.23 |
| MACD Histogram | -0.1914 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.80 | ||||
| Resistance 3 (R3) | 7.80 | 7.62 | 7.71 | ||
| Resistance 2 (R2) | 7.62 | 7.48 | 7.62 | 7.68 | |
| Resistance 1 (R1) | 7.44 | 7.40 | 7.53 | 7.44 | 7.65 |
| Pivot Point | 7.26 | 7.26 | 7.31 | 7.26 | 7.26 |
| Support 1 (S1) | 7.08 | 7.12 | 7.17 | 7.08 | 6.87 |
| Support 2 (S2) | 6.90 | 7.04 | 6.90 | 6.84 | |
| Support 3 (S3) | 6.72 | 6.90 | 6.81 | ||
| Support 4 (S4) | 6.72 |
